HALO Wins Court Order Blocking Merck's Keytruda SC in Europe

A Dutch court ruled that Merck’s Keytruda subcutaneous formulation infringes a Halozyme MDASE patent and ordered Merck to stop making and selling it in eight European markets; the order does not affect Keytruda IV. Merck disputes the ruling and is evaluating next steps, while Halozyme’s separate ENHANZE business—used in 10 commercialized products across more than 100 markets—is unaffected. The ruling could strengthen Halozyme’s leverage in licensing or settlement talks, but no financial benefit is guaranteed; the article reports HALO shares are up 65% year to date versus 1% for the industry.

Analysis

The market-relevant issue is not near-term loss of Keytruda demand: IV remains available, which cushions Merck’s revenue while leaving a potential disadvantage in convenience and administration capacity. The larger uncertainty is whether SC access becomes a meaningful franchise-preservation tool ahead of biosimilar entry, and whether Merck can restore it through appeal, redesign, or licensing. The article does not quantify European SC uptake or the economics of switching patients, so the injunction alone does not support a reliable earnings haircut.

For Halozyme, the ruling may improve settlement leverage, but that value is contingent on surviving appeal and producing royalties or other measurable consideration. Its separate ENHANZE platform—and therefore the cited J&J and argenx products—should not be treated as directly impaired or enhanced by this MDASE dispute. Any broader read-through to platform IP is speculative. After HALO’s reported 65% YTD advance, investors may already be paying for legal wins before cash flows are visible; upside could be asymmetric only if a durable ruling yields a material deal.

Near term, watch Merck’s appeal/stay and whether sales are actually interrupted; over 1–3 months, rulings in Germany and the U.S. could shape bargaining power. Over 6–18 months, sustained exclusion could shift SC share or prompt a license, while reversal or a workaround would sharply reduce Halozyme’s litigation optionality. Merck’s strongest offset is continued IV availability; its longer-run exposure depends on SC conversion and biosimilar erosion, not this order alone.

Key Decisions for Investors

• Do not chase HALO on the ruling alone. Treat it as a catalyst watch: add only after confirming the injunction is in force and monitoring for a settlement, royalty terms, or an upheld decision that makes the value quantifiable. The reported YTD rally raises the risk of a sell-the-news reaction.
• Keep MRK exposure sized around the broader Keytruda franchise rather than assuming an immediate sales cliff. Consider a modest, time-limited hedge only if the injunction is not stayed and evidence shows SC patients cannot be redirected effectively to IV; reassess on appeal or stay news.
• Track the Dutch appeal/stay, the status of the German order, U.S. case milestones, and company disclosures on affected-market SC sales, patient switching, and any license economics. Falsifiers for the HALO upside case are a reversal, a stay followed by resumed sales, or a workaround that avoids meaningful payments.
• No trade implication for JNJ or ARGX from this ruling on the supplied facts: ENHANZE is identified as distinct from the disputed MDASE technology. Revisit only if separate disclosures indicate an ENHANZE-specific legal or commercial issue.